Only small changes in lipid profile and no change in arterial inflammation (measured by FDG-PET) in both TNFi/MTX and triple therapy groups over a 24 week period in the TARGET trial. What do you think could account for this? Follow-up period too short? @RheumNow ABST0254 #ACR22 https://t.co/JMJ7WgXyJX